Anti-TNF continuation after 24 weeks of pregnancy beneficial to persons with IBD, does not affect neonatal outcomes
New study IDs what brings our senses and thoughts together
27 September 2022Probiotic prescriptions for premature babies to reduce disease risk
27 September 2022Anti-TNF continuation after 24 weeks of pregnancy beneficial to persons with IBD, does not affect neonatal outcomes
A 10-year emulation trial of pregnant persons with inflammatory bowel disease (IBD) has found that continuation of anti–tumor necrosis factor (anti-TNF) treatment after 24 weeks of pregnancy appears beneficial regarding IBD activity and prematurity, while not affecting neonatal outcomes and serious infections in the offspring. The findings are published in Annals of Internal Medicine.
